Jeffrey Gundlach’s Blood Feud With Morningstar: The Inside Story – ValueWalk Premium

Jeffrey Gundlach’s Blood Feud With Morningstar: The Inside Story

Is the genius of DoubleLine founder Jeffrey Gundlach on display resulting from his recent disagreement of opinion with Morningstar? And what exactly is the special sauce behind DoubleLine’s rather dramatic out-performance relative to industry benchmarks?

As DoubleLine today announces total firm net inflows of $688.7 million in July, with the flagship DoubleLine Total Return Bond Fund (DBTLX) snatching as much as $390.4 million in new assets alone, the firm founded in the wake of an . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds. 📈

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

Sign up now. 👇

CLICK HERE TO TRY IT OUT

 

0